Everything below concerns Lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Homeobox protein cut-like 1 is a protein that in humans is encoded by the CUX1 gene (previously CUTL1). This protein is a homeodomain protein. The term "cut" in the name "cut-like 1" derives from the "cut wing" phenotype observed in a mutant of Drosophila melanogaster. In mammals, a CCAAT-displacement activity was originally described in DNA binding assays. The human gene was identified following purification of the CCAAT-displacement protein (CDP) and has been successively been called CDP, Cut-like 1 (CUTL1), CDP/Cut and finally, CUX1. (Consequently, a literature search for CUX1 fails to bring up many of the earlier studies). Cut homeobox genes are present in all metazoans. In mammals, CUX1 is expressed ubiquitously in all tissues. A second gene, called CUX2, is expressed primarily in neuronal cells.
chemical substance Also pure substance or simply substance. A form of matter that has constant chemical composition and characteristic properties and which cannot be separated into simpler components by purely physical methods (i.e. without breaking chemical bonds). It is often called a pure substance to distinguish it from a mixture.
For services to Youth Football. Jane Loveys. Director, Campus Services, University of Bath. For services to Higher Education. Geoffrey Lowe. Crew Manager, Norfolk Fire and Rescue Service. For services to the community in Norfolk. Joan Lynas. For services to the Girls' Brigade and to the community in Newtownabbey, Northern Ireland. Kevin Philip Macey. Head of Major Crime Review, Essex Police. For services to Policing. John Alexander Mackintosh. Fundraiser, Cancer Research UK. For voluntary services to Cancer Patients and to the community in Elgin. Veronica Maclean. Patron, Moray Fundraising Group, Marie Curie. For voluntary services to Cancer Patients in Moray. Mubarak Hussain Mahmed. Well-Being and Engagement Co-ordinator, First Bus North and West Yorkshire. For services to Mental Health. Christopher Marsay. Watch Manager, Cleveland Fire and Rescue Service. For services to the community in North Yorkshire. Jeremy Paul McCluskey. Front of House and Security Guard, G4S Security. For Public Service, particularly during Covid-19. Robert John McCormick. Security Team Leader, Hillsborough Castle and Gardens. For Public Service. Jodie McFarlane. Detective Constable, Police Service of Scotland. For services to Children and Families in Ayrshire. Patrick Eugene McGeehan. Coach, Santos Football Club. For voluntary service to Association Football in Northern Ireland. Myrtle Edna McIlveen. Volunteer Manager, Killyleagh Community Charity Shop. For voluntary services to the community in County Down. Matthew McKenzie. Insight Volunteer, Carers UK. For services to Carers.
== ADLM Members == ADLM's approximately 8,000 members come from all areas of lab medicine—clinical and research laboratories, diagnostic companies, government agencies, original equipment manufacturers, and more. Collectively they develop and run lab tests and lab instruments used throughout healthcare. They also manage labs, conduct research involving biomarkers, and promote accurate diagnostic testing. ADLM represents the diverse interests of a global lab community: its members come from 110 countries and hold the spectrum of lab-related professional degrees, certifications, and credentials.
=== Legal status === Butorphanol is listed under the Single Convention on Narcotic Drugs 1961 and in the United States is a Schedule IV controlled substance with a DEA ACSCN of 9720. The free base conversion ratio of the hydrochloride is 0.69. Butorphanol was originally a Schedule II controlled substance and was later decontrolled at one point.
Sources: en.wikipedia.org
an organ's blood flow. Each organ will have its own specific clearance conditions, which will relate to its mode of action. The «renal clearance» rate will be determined by factors such as the degree of plasma protein binding as the drug will only be filtered out if it is in the unbound free form, the degree of saturation of the transporters (active secretion depends on transporter proteins that can become saturated) or the number of functioning nephrons (hence the importance of factors such as kidney failure). As «hepatic clearance» is an active process it is therefore determined by factors that alter an organism's metabolism such as the number of functioning hepatocytes, this is the reason that liver failure has such clinical importance.
Chronic Somogyi rebound is a contested explanation of phenomena of elevated blood sugars experienced by diabetics in the morning. Also called the Somogyi effect and posthypoglycemic hyperglycemia, it is a rebounding high blood sugar that is a response to low blood sugar. When managing the blood glucose level with insulin injections, this effect is counter-intuitive to people who experience high blood sugar in the morning as a result of an overabundance of insulin at night. This theoretical phenomenon was named after Michael Somogyi [suh MOE jee], a Hungarian-born professor of biochemistry at the Washington University and Jewish Hospital of St. Louis, who prepared the first insulin treatment given to a child with diabetes in the US in October 1922. Somogyi showed that excessive insulin makes diabetes unstable and first published his findings in 1938. Compare with the dawn phenomenon, which is a morning rise in blood sugar in response to waning insulin and a growth hormone surge (that further antagonizes insulin).
After the end of World War II, Enewetak came under the control of the United States as part of the Trust Territory of the Pacific Islands, until the independence of the Marshall Islands in 1986. During its tenure, the United States evacuated the local residents many times, often involuntarily. The atoll was used for nuclear testing, as part of the Pacific Proving Grounds. Before testing commenced, the U.S. exhumed the bodies of United States servicemen killed in the Battle of Enewetak and returned them to the United States to be re-buried by their families. Forty-three nuclear tests were fired at Enewetak from 1948 to 1958. The first hydrogen bomb test, code-named Ivy Mike, occurred in late 1952 as part of Operation Ivy; it vaporized the islet of Elugelab and created two new elements: Fermium and Einsteinium. This test included B-17 Flying Fortress drones to fly through the radioactive cloud to test onboard samples. B-17 mother ships controlled the drones while flying within visual distance of them. In all, 16 to 20 B-17s took part in this operation, of which half were controlling aircraft and half were drones. To examine the explosion clouds of the nuclear bombs in 1957/58, several rockets (mostly from rockoons) were launched. One USAF airman, Jimmy Robinson, was lost at sea during the tests. Robinson's F-84 Thunderjet crashed and sank 3.5 miles (5.6 km) short of the island. Robinson's body was never recovered.
DABA analogues A novel family of zinc-targeting diaminobenzoic acid (DABA) compounds were rationally designed and developed in 2013, displaying micromolar potency for ERAP1 inhibition (compound 2, IC50 = 2 μM, Table 1). Moderate selectivity over ERAP2 and IRAP with additional optimization efforts based on extensive investigation of SAR has been achieved.
Sources: en.wikipedia.org
The observation that living things inherit traits from their parents has been used since prehistoric times to improve crop plants and animals through selective breeding. The modern science of genetics, seeking to understand this process, began with the work of the Augustinian friar Gregor Mendel in the mid-19th century.
In the Cape Colony, increasing tensions between some Dutch Settlers and the British colonial authorities led to a wave of Boer (also known as Voortrekkers) migration northwards from 1836 onwards in order to establish autonomous Boer states independent of British control. The Boers settlers began moving across the Orange River northwards. While travelling they first collided with the Ndebele kingdom, and then with Dingane's Zulu kingdom. In October 1837, the Voortrekker leader Piet Retief visited Dingane at his royal kraal to negotiate a land deal for the voortrekkers. In November, about 1,000 Voortrekker wagons began descending the Drakensberg mountains from the Orange Free State into what is now KwaZulu-Natal. Dingane asked that Retief and his party retrieve some cattle stolen from him by a local chief as part of the treaty for land for the Boers. This Retief and his men did, returning on 3 February 1838. The next day, a treaty was signed, wherein Dingane ceded all the land south of the Tugela River to the Mzimvubu River to the Voortrekkers. Celebrations followed. On 6 February, at the end of the celebrations, Retief's party were invited to a dance, and asked to leave their weapons behind. At the peak of the dance, Dingane leapt to his feet and yelled "Bambani abathakathi!" (isiZulu for "Seize the wizards"). Retief and his men were overpowered, taken to the nearby hill kwaMatiwane, and executed. Some allege that they were killed for withholding some of the cattle they recovered, but it is likely that the deal was a plot to overpower the Voortrekkers.
Affinity purification purifies proteins by retaining them on a column through their affinity to antibodies, enzymes, or receptors that have been immobilised on the column. Filtration is a mechanical method to separate solids from liquids or gases by passing the feed stream through a porous sheet such as a cloth or membrane, which retains the solids and allows the liquid to pass through. Centrifugation is a process that uses an electric motor to spin a vessel of fluid at high speed to make heavier components settle to the bottom of the vessel. Evaporation removes volatile liquids from non-volatile solutes, which cannot be done through filtration due to the small size of the substances. Liquid–liquid extraction removes an impurity or recovers a desired product by dissolving the crude material in a solvent in which other components of the feed material are soluble. Crystallization separates a product from a liquid feed stream, often in extremely pure form, by cooling the feed stream or adding precipitants that lower the solubility of the desired product so that it forms crystals. The pure solid crystals are then separated from the remaining liquor by filtration or centrifugation. Recrystallization: In analytical and synthetic chemistry work, purchased reagents of doubtful purity may be recrystallised, e.g. dissolved in a very pure solvent, and then crystallized, and the crystals recovered, in order to improve and/or verify their purity. Trituration removes highly soluble impurities from usually solid insoluble material by rinsing it with an appropriate solvent.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.